ENHERTU® ▼ (TRASTUZUMAB DERUXTECAN) ACCEPTED FOR USE WITHIN NHS SCOTLAND EARLIER IN THE TREATMENT PATHWAY FOR HER2-POSITIVE METASTATIC BREAST CANCER
April 12, 2023Business Services
Daiichi Sankyo UK Limited and AstraZeneca UK Limited welcome the news that the Scottish Medicines Consortium (SMC) has accepted Enhertu®▼ …
Almirall, the first to assess wellbeing in a dermatology clinical study
April 12, 2023Business Services
BARCELONA, Spain. April 12, 2023 – Almirall, S.A. (ALM), a global biopharmaceutical company focused on skin health, today announced the …
Liberal states begin stockpiling abortion medications following Texas court ruling
April 12, 2023Medical Communications
Various liberal US states, including California and Massachusetts, have begun stockpiling abortion medications following a Texas judge Matthew Kacsmaryk’s attempt …
Moderna announces mixed success clinical updates for mRNA pipeline
April 12, 2023Research and Development
Biotechnology company Moderna has announced clinical updates detailing the expansion and advancement of its mRNA pipeline, which includes treatments for …
ImaginAb signs new license and supply agreement with Leucid Bio for CD8 ImmunoPET technology
April 12, 2023Sales and Marketing
Biotechnology company ImaginAb has announced that it has signed a new non-exclusive License and Supply Agreement (LSA) with Leucid Bio. …
Cognizant and Boehringer Ingelheim collaborate on integrated cloud platform to improve therapy development
April 12, 2023Medical Communications
US-based Cognizant and biopharmaceutical company Boehringer Ingelheim have announced a partnership to collaborate on ensuring the quality, and increasing the …
CENTOGENE Extends Strategic Partnership With Takeda to Continue Providing Access to Genetic Testing for Patients With Lysosomal Storage Disorders
April 11, 2023Business Services
CAMBRIDGE, Mass., ROSTOCK, Germany and BERLIN, April 11, 2023 (GLOBE NEWSWIRE) — Centogene N.V. (Nasdaq: CNTG), the essential life science …
Molecular Templates announces hold for phase 1 study
April 11, 2023Research and Development
Molecular Templates has announced that the FDA has placed a partial hold on its phase 1 study for MT-0169 based …
FDA authorises marketing of MISHA Knee System for patients with knee osteoarthritis
April 11, 2023Medical Communications
Medical device company, Moximed, has announced that the FDA granted marketing authorisation of its MISHA Knee System, an implantable shock …
Nuance Pharma Announces Dosing of First Patient in ENHANCE – China Phase 3 Trial for COPD
April 11, 2023Business Services
LONDON and RALEIGH, N.C., April 11, 2023 – Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage …
Pharming announces the first commercial shipments of Joenja® (leniolisib) to patients in the U.S.
April 11, 2023Business Services
Leiden, The Netherlands, April 11, 2023: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM / Nasdaq: PHAR) announces the first commercial …
Avacta Opens First Two US Clinical Investigator Sites for AVA6000 Phase 1 Clinical Study
April 6, 2023Business Services
Avacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted oncology drugs and powerful diagnostics, announces the opening …
AstraZeneca’s Lynparza approved by NHS England
April 6, 2023Medical Communications
NHS England has approved the use of AstraZeneca’s Lynparza (olaparib) for the treatment of patients with breast cancer and prostate …
Synapse receives FDA approval for its NeuRx DPS to treat patients with stable SCI
April 6, 2023Research and Development
Synapse Biomedical has announced that it has gained premarket approval (PMA) from the FDA for its NeuRxDiaphragm Pacing System (NeuRx …
Innova Care Concepts expand their support to the medical negligence sector with the acquisition of Nurture Group Ltd.
April 5, 2023Business Services
Press Release, Wednesday 5th April 2023, London… As part of a long-term strategy to increase its home adaptation services across …
Ipsen’s response to NICE’s decision on Cabometyx® (cabozantinib) for previously treated differentiated thyroid cancer unsuitable for or refractory to radioactive iodine
April 5, 2023Business Services
SLOUGH, UK, 5th April 2023 – Ipsen is disappointed that the National Institute for Health and Care Excellence (NICE) …
Syncona Appoints Roel Bulthuis as Managing Partner
April 5, 2023Business Services
05 April 2023 Syncona Ltd, a leading healthcare company focused on creating, building and scaling global leaders in life …
First Patient Dosed in Fifth Cohort of AVA6000 Phase Ia Dose Escalation Study
April 5, 2023Business Services
Avacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted oncology drugs and powerful diagnostics, announces that the …
BenevolentAI announces top-line Phase IIa results for its topical pan-Trk inhibitor BEN-2293 (1%) in mild-to-moderate atopic dermatitis
April 5, 2023Business Services
London, UK, 5 April 2023: BenevolentAI (“BenevolentAI” or the “Company”) (Euronext Amsterdam: BAI) announces top-line results from its Phase IIa, …
AstraZeneca reports positive results of drug combination in late-stage ovarian cancer trial
April 5, 2023Medical Communications
AstraZeneca has announced positive high-level results from an interim analysis of the DUO-O phase 3 trial assessing a combination of …
Latest content
Long-acting therapies set to reshape HIV treatment market
MHRA approves Romvimza for tenosynovial giant cell tumour
